Navigation Links
Mylan Wins Its Amlodipine Case With Pfizer

PITTSBURGH, Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Court of Appeals for the Federal Circuit today granted its motion for a reversal of the district court judgment in its patent infringement litigation with Pfizer concerning amlodipine besylate.

On February 22, 2007, the district court for the Western District of Pennsylvania had ruled in favor of Pfizer and Mylan immediately appealed and has continued to fully expect a reversal of the decision. Mylan was able to launch its amlodipine products following a March 22, 2007 decision by the U.S. Court of Appeals for the Federal Circuit that claims 1-3 of the amlodipine '303 patent were invalid.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer commented: "We are pleased to have prevailed in our amlodipine besylate litigation and the judicial system ultimately confirmed the position that we were the first to assert and have consistently maintained concerning this product for over four years. We are further pleased that our first to market generic amlodipine products have saved patients, corporations, the government and taxpayers hundreds of millions of dollars in healthcare costs."

Amlodipine Besylate Tablets are the generic version of Pfizer's Norvasc(R) Tablets, which had U.S. sales of approximately $2.7 billion for the 12-month period ending Dec. 31, 2006, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.


'"/>




Page: 1

Related medicine news :

1. Mylan Announces Final FDA Approval for Fluoxetine Capsules
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Pfizer unveils anti-smoking drug
4. The Effectiveness Of The Breast Cancer Drug By Pfizer
5. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
6. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
7. Pfizer’s Eraxis Approved By The FD
8. Pfizer Launches Viagra For Lung Disease In UK
9. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
10. Pfizer Commences Its Advertising for Celebrex with All the Warnings
11. FDA Approves Pfizer’s Anti-smoking Dru
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: